close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Star Therapeutics

News headline image
Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies
From Star Therapeutics
Via Business Wire
News headline image
Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies
From Star Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.